Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring
{{output}}
With the recent conditional approval of resmetirom by the US Food and Drug Administration, the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) has potentially entered a new era, requiring a comprehensive understanding of the stren... ...
